Cancer Evolution Constrained by the Immune Microenvironment

被引:359
作者
McGranahan, Nicholas [1 ]
Swanton, Charles [1 ,2 ]
机构
[1] UCL, Canc Inst, Canc Res UK Lung Canc Ctr Excellence, Paul OGorman Bldg,72 Huntley St, London WC1E 6BT, England
[2] Francis Crick Inst, Translat Canc Therapeut Lab, 1 Midland Rd, London NW1 1AT, England
基金
英国医学研究理事会;
关键词
CHECKPOINT BLOCKADE;
D O I
10.1016/j.cell.2017.08.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumor development is a Darwinian evolutionary process, involving the interplay between cancer subclones and the local immune microenvironment. These complex interactions are highlighted in this issue of Cell by the results from Jimenez-Sanchez et al. of a deep analysis of one patient with advanced serous carcinoma of the ovary.
引用
收藏
页码:825 / 827
页数:4
相关论文
共 6 条
[1]   Evolutionary Determinants of Cancer [J].
Greaves, Mel .
CANCER DISCOVERY, 2015, 5 (08) :806-820
[2]   Influence of tumour micro-environment heterogeneity on therapeutic response [J].
Junttila, Melissa R. ;
de Sauvage, Frederic J. .
NATURE, 2013, 501 (7467) :346-354
[3]   Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade [J].
McGranahan, Nicholas ;
Furness, Andrew J. S. ;
Rosenthal, Rachel ;
Ramskov, Sofie ;
Lyngaa, Rikke ;
Saini, Sunil Kumar ;
Jamal-Hanjani, Mariam ;
Wilson, Gareth A. ;
Birkbak, Nicolai J. ;
Hiley, Crispin T. ;
Watkins, Thomas B. K. ;
Shafi, Seema ;
Murugaesu, Nirupa ;
Mitter, Richard ;
Akarca, Ayse U. ;
Linares, Joseph ;
Marafioti, Teresa ;
Henry, Jake Y. ;
Van Allen, Eliezer M. ;
Miao, Diana ;
Schilling, Bastian ;
Schadendorf, Dirk ;
Garraway, Levi A. ;
Makarov, Vladimir ;
Rizvi, Naiyer A. ;
Snyder, Alexandra ;
Hellmann, Matthew D. ;
Merghoub, Taha ;
Wolchok, Jedd D. ;
Shukla, Sachet A. ;
Wu, Catherine J. ;
Peggs, Karl S. ;
Chan, Timothy A. ;
Hadrup, Sine R. ;
Quezada, Sergio A. ;
Swanton, Charles .
SCIENCE, 2016, 351 (6280) :1463-1469
[4]  
Stott Rebecca, 2012, Darwin's Ghosts: In Search of the First Evolutionists
[5]   Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy [J].
Topalian, Suzanne L. ;
Taube, Janis M. ;
Anders, Robert A. ;
Pardoll, Drew M. .
NATURE REVIEWS CANCER, 2016, 16 (05) :275-287
[6]   Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer [J].
Topalian, Suzanne L. ;
Hodi, F. Stephen ;
Brahmer, Julie R. ;
Gettinger, Scott N. ;
Smith, David C. ;
McDermott, David F. ;
Powderly, John D. ;
Carvajal, Richard D. ;
Sosman, Jeffrey A. ;
Atkins, Michael B. ;
Leming, Philip D. ;
Spigel, David R. ;
Antonia, Scott J. ;
Horn, Leora ;
Drake, Charles G. ;
Pardoll, Drew M. ;
Chen, Lieping ;
Sharfman, William H. ;
Anders, Robert A. ;
Taube, Janis M. ;
McMiller, Tracee L. ;
Xu, Haiying ;
Korman, Alan J. ;
Jure-Kunkel, Maria ;
Agrawal, Shruti ;
McDonald, Daniel ;
Kollia, Georgia D. ;
Gupta, Ashok ;
Wigginton, Jon M. ;
Sznol, Mario .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2443-2454